Compare Novo Nordisk A/S (NVO) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Global X Defense Tech ETF — how do they compare? Novo Nordisk A/S trades at $46.18 (market cap $207.85B), while Global X Defense Tech ETF trades at $69.69. The key difference: Novo Nordisk A/S pays a 3.81% dividend while Global X Defense Tech ETF pays none, and Global X Defense Tech ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | SHLD | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Sector/Thematic |
52-Week High | $63.98 | $78.02 |
52-Week Low | $35.29 | $58.20 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
SHLD, the Global X Defense Tech ETF, trades at $69.74, down slightly by 0.16% today. Technical indicators show a bullish trend with strong moving average signals, though oscillators are neutral and RSI levels suggest overbought conditions. Recent news highlights increased institutional investment, with firms like Focus Financial Network raising stakes by 55.4% in Q2 2026 (Defense World, 2026-08-11). The ETF benefits from global defense spending trends, including a $20 billion UK military overhaul (Zacks Investment Research, 2026-07-02).
The outlook for SHLD is positive, driven by rising global defense budgets and technological advancements in defense sectors. Investment opportunities include diversified exposure to defense innovation, supported by institutional accumulation. Risks involve geopolitical shifts, potential tariff impacts from policies like Trump's new tariffs (Fool - Investing News, 2026-08-04), and valuation pressures if growth slows. The ETF's performance hinges on sustained military expenditure increases and contract awards.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
